Clinical trials
Moderately to Severely Active Crohns Disease clinical trials
Below are recruiting moderately to severely active crohns disease clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Dothan, AlabamaAges 16–80 - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Dothan, AlabamaAges 16–80 - NCT06754891RecruitingPhase 1
A study of TQH3906 for moderate to severe inflammatory bowel disease
This trial tests a new medicine (TQH3906) for people with moderate to severe ulcerative colitis or Crohn's disease that hasn't improved with other treatments. The goal is to see if it can help control inflammation in the gut.
Bengbu, AnhuiAges 18–75 - NCT06721962RecruitingPhase 1/Phase 2
Testing an experimental treatment for moderate to severe Crohn's disease
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Scottsdale, ArizonaAges 18–65 - NCT06456593RecruitingPhase 2
Obefazimod for moderate to severe Crohn's disease
This trial tests an experimental oral medication called obefazimod for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments have not worked well.
Fairhope, AlabamaAges 18–75 - NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Dothan, AlabamaAges 16–80 - NCT06332534RecruitingPhase 3
Upadacitinib in children with moderate to severe Crohn's disease
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
Oakland, CaliforniaAges 2–17 - NCT06274554RecruitingPhase 3
Testing Antifungal Therapy for Crohn's Disease
This study tests whether adding an antifungal drug (fluconazole) to standard Crohn's disease treatment helps improve symptoms. It's for people with mild to moderate Crohn's who have not used antifungal medications recently.
New York, New YorkAges 18 years+ - NCT06257706RecruitingPhase 4
Healing the bowel wall in Crohn's disease with vedolizumab
This study tests whether a medicine called vedolizumab can help heal all layers of the bowel wall in Crohn's disease. It uses a special ultrasound to see inside the bowel, aiming for deeper healing than usual.
Los Angeles, CaliforniaAges 18–80 - NCT06233461RecruitingPhase 2
A study of TAK-279 for Crohn's disease
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Murrieta, CaliforniaAges 18–75 - NCT06226883RecruitingPhase 2
Testing MORF-057 for moderate to severe Crohn's disease
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Lancaster, CaliforniaAges 18–85 - NCT05428345Recruiting
Shot of vedolizumab skin injection for active bowel inflammation
This study tests whether a weekly/regular skin injection version of vedolizumab can help adults with moderate to severe ulcerative colitis or Crohn’s disease who did not fully respond to other treatments or TNF blockers. It may help by moving you from an intravenous (IV) infusion to a self/clinic injection option.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT05837897RecruitingPhase 3
Vedolizumab for adults with moderate-to-severe Crohn’s
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
Hefei, AnhuiAges 18–80 - NCT06023030Recruiting
Observing how upadacitinib works for Crohn's disease in Japan
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
Anjo-shi, Aichi-kenAges 15 years+ - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 2–17 - NCT05923073RecruitingPhase 3
Guselkumab for children with active Crohn’s disease
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Los Angeles, CaliforniaAges 2–17 - NCT04779320RecruitingPhase 3
Vedolizumab for teens with moderate to severe Crohn's
This trial tests vedolizumab to treat children and teens with moderate to severe Crohn’s disease when standard treatments haven’t worked or caused side effects. It may help reduce gut inflammation and symptoms and help some patients stay healthier over time.
Phoenix, ArizonaAges 2–17 - NCT03167437RecruitingPhase 1/Phase 2
Vorinostat for uncontrolled Crohn’s or ulcerative colitis
This early-phase study tests vorinostat to reduce gut inflammation in people with moderate-to-severe Crohn’s disease, ulcerative colitis, or certain colitis patterns linked to chronic granulomatous disease (CGD). It also looks at whether the study’s consent process is clear and understood before starting treatment.
Bethesda, MarylandAges 18–65 - NCT07077746RecruitingPhase 2
Stem cells for Crohn's disease
This trial tests whether a type of stem cell called HB-adMSCs can help treat Crohn's disease. It is for adults with mild to moderate Crohn's who have certain signs of inflammation in their blood and recent imaging of their condition.
Sugar Land, TexasAges 18–65 - NCT05387031Recruiting
Ustekinumab for painful Crohn’s bowel narrowing
This trial tests ustekinumab, a medicine that calms immune inflammation, to see if it can improve symptoms in people with Crohn’s disease that causes bowel narrowing. It may help if your Crohn’s symptoms come from strictures (narrowed areas) seen on scans or endoscopy.
Beijing, Beijing MunicipalityAges 18–65 - NCT04263831RecruitingPhase 1/Phase 2
Low-dose IL-2 to treat Crohn’s disease flare-ups
This trial tests a low dose of IL-2 to reduce inflammation and help control Crohn’s disease symptoms. It’s for people whose Crohn’s disease hasn’t responded to at least one standard treatment or who need steroids to stay under control.
Boston, MassachusettsAges 12–80 - NCT07444060Recruiting
Guselkumab vs Ustekinumab for stricturing Crohn's disease
This study compares two medicines, Guselkumab and Ustekinumab, for people with Crohn's disease that causes narrowing (strictures) in the bowel. It aims to find which works better to improve symptoms and avoid the need for more procedures.
Hangzhou, ZhejiangAges 18–80 - NCT06958536RecruitingPhase 2
Study of brivekimig for moderate-to-severe Crohn's disease
This trial tests a new medicine called brivekimig for people with moderate-to-severe Crohn's disease. It aims to see if the drug can reduce symptoms and inflammation better than standard treatments.
Tucson, ArizonaAges 18–75 - NCT07531342Recruiting
Brain Stimulation and Diet for Severe Crohn's Disease
This study tests whether repetitive transcranial magnetic stimulation (a non-invasive brain treatment) combined with an anti-inflammatory diet can help people with severe, treatment-resistant Crohn's disease feel better. The brain stimulation uses magnetic pulses on the scalp to reduce inflammation and improve symptoms.
Giza, Giza GovernorateAges 40–60
Hear when a new Moderately to Severely Active Crohns Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderately to severely active crohns disease?
- Yes. Clin2 currently lists 87 recruiting moderately to severely active crohns disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderately to severely active crohns disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderately to severely active crohns disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.